Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
企業コードIBO
会社名Impact Biomedical Inc
上場日Sep 16, 2024
最高経営責任者「CEO」Heuszel (Frank D)
従業員数2
証券種類Ordinary Share
決算期末Sep 16
本社所在地1400 Broadfield Blvd.
都市HOUSTON
証券取引所NASDAQ OMX – NASDAQ Basic Amex
国United States of America
郵便番号77084
電話番号15852321500
ウェブサイトhttps://www.impactbiomedinc.com/
企業コードIBO
上場日Sep 16, 2024
最高経営責任者「CEO」Heuszel (Frank D)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし